BNTX:NSD-BioNTech SE (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 171.81

Change

+9.18 (+5.64)%

Market Cap

USD 39.94B

Volume

1.16M

Avg Analyst Target

USD 206.18 (+20.00%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BNTX Stock Forecast & Price:
Based on the BioNTech SE stock forecasts from 9 analysts, the average analyst target price for BioNTech SE is USD 206.18 over the next 12 months. BioNTech SE’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of BioNTech SE is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, BioNTech SE’s stock price was USD 171.81. BioNTech SE’s stock price has changed by +1.38% over the past week, +6.75% over the past month and -41.15% over the last year.

About BioNTech SE (BNTX:NSD)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/I ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+1.15 (+0.15%)

USD81.40B 15.14 12.35
VRTX Vertex Pharmaceuticals Inc

+3.74 (+1.18%)

USD80.04B 24.25 17.39
MRNA Moderna Inc

+5.70 (+3.18%)

USD67.59B 6.10 4.60
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
GMAB Genmab AS

+0.12 (+0.26%)

USD29.93B 36.52 3.71
ALNY Alnylam Pharmaceuticals Inc

+6.68 (+2.89%)

USD28.46B N/A -29.83
SGEN Seagen Inc

+5.88 (+4.93%)

USD22.16B 55.02 -38.32
ARGX argenx NV ADR

+5.15 (+1.34%)

USD21.93B N/A -22.20
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
BMRN Biomarin Pharmaceutical Inc

+0.70 (+0.68%)

USD19.00B 217.49 88.52

ETFs Containing BNTX

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Biotech ETF 0.00 % 0.35 %

+2.41 (+1.46%)

USD0.48B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

+0.22 (+0.44%)

USD0.02B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+1.52 (+2.52%)

USD0.10B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

+1.59 (+1.03%)

USD1.35B
FPXI First Trust International.. 0.00 % 0.70 %

+0.56 (+1.43%)

USD0.29B
FPXE First Trust IPOX Europe E.. 0.00 % 0.70 %

+0.18 (+0.89%)

USD5.42M
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

+0.40 (+1.48%)

USD0.18B
AADR AdvisorShares Dorsey Wrig.. 0.00 % 1.00 %

+0.05 (+0.10%)

USD0.04B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.12 (+1.92%)

USD0.46B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.07 (+1.34%)

USD0.46B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.11 (+1.73%)

USD0.46B
GERM ETFMG Treatments Testing .. 0.00 % 0.68 %

+0.18 (+0.76%)

USD0.02B
FBT:LSE First Trust Global Funds .. 0.00 % 0.60 %

+15.50 (+1.01%)

USD6.54M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.60 %

+0.27 (+1.42%)

USD6.66M
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.19 %

+0.18 (+0.84%)

USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -33.36% 70% C- 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.36% 70% C- 42% F
Trailing 12 Months  
Capital Gain -39.55% 68% D+ 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.55% 67% D+ 39% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 104.27% 95% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 104.27% 95% A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 156.73% 9% F 6% F
Risk Adjusted Return 66.52% 98% A+ 94% A
Market Capitalization 39.94B 100% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 3.92 55% F 86% B
Price/Book Ratio 2.13 48% F 39% F
Price / Cash Flow Ratio 44.89 2% F 6% F
EV/EBITDA 1.87 7% F 38% F
Management Effectiveness  
Return on Equity 76.24% 99% A+ 98% A+
Return on Invested Capital 152.53% 97% A+ 97% A+
Return on Assets 42.83% 100% A+ 100% A+
Debt to Equity Ratio 1.44% 81% B- 82% B-
Technical Ratios  
Dividend Yield 1.33% 33% F 21% F
Short Ratio 1.76 71% C- 61% D-
Short Percent 2.94% 55% F 44% F
Beta 0.16 89% B+ 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.